Status: Recruiting
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpression.
Participants needed: 100
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Cogent Biosciences, Inc.Updated: Feb 27, 2026Locations: 6
Eligibility criteria
Part A: Locally advanced, metastatic, and/or unresectable solid tumor with docum... [+5]
Received small molecule chemotherapy or anticancer therapies or radiotherapy wit... [+5]